IL2 and colitis: Another study employed a combination of an IL-2/IL-2 agonist immunocomplex with IL-5RA antagonist in the DSS colitis model, showing superior therapeutic efficacy compared to using the blocking IL-2/IL-2 agonist immunocomplex alone.